Eric I Richman - Net Worth and Insider Trading

Eric I Richman Net Worth

The estimated net worth of Eric I Richman is at least $1 Million dollars as of 2024-11-13. Eric I Richman is the Director of ADMA Biologics Inc and owns about 36,530 shares of ADMA Biologics Inc (ADMA) stock worth over $795,623. Eric I Richman is the Director of Gain Therapeutics Inc and owns about 304,458 shares of Gain Therapeutics Inc (GANX) stock worth over $631,750. Eric I Richman is also the Director of NeuBase Therapeutics Inc and owns about 3,635 shares of NeuBase Therapeutics Inc (NBSE) stock worth over $1,374. Details can be seen in Eric I Richman's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Eric I Richman has not made any transactions after 2024-07-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Eric I Richman

To

Eric I Richman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Eric I Richman owns 4 companies in total, including NeuBase Therapeutics Inc (NBSE) , ADMA Biologics Inc (ADMA) , and Altimmune Inc (ALT) among others .

Click here to see the complete history of Eric I Richman’s form 4 insider trades.

Insider Ownership Summary of Eric I Richman

Ticker Comapny Transaction Date Type of Owner
NBSE NeuBase Therapeutics Inc 2022-03-04 director
ADMA ADMA Biologics Inc 2018-06-08 director
ALT Altimmune Inc 2009-01-21 SVP & Business Development
LIMIT LIMIT 2024-07-01 director

Eric I Richman Latest Holdings Summary

Eric I Richman currently owns a total of 3 stocks. Among these stocks, Eric I Richman owns 36,530 shares of ADMA Biologics Inc (ADMA) as of June 8, 2018, with a value of $795,623 and a weighting of 55.69%. Eric I Richman owns 304,458 shares of Gain Therapeutics Inc (GANX) as of July 1, 2024, with a value of $631,750 and a weighting of 44.22%. Eric I Richman also owns 3,635 shares of NeuBase Therapeutics Inc (NBSE) as of March 4, 2022, with a value of $1,374 and a weighting of 0.1%.

Latest Holdings of Eric I Richman

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ADMA ADMA Biologics Inc 2018-06-08 36,530 21.78 795,623
GANX Gain Therapeutics Inc 2024-07-01 304,458 2.08 631,750
NBSE NeuBase Therapeutics Inc 2022-03-04 3,635 0.38 1,374

Holding Weightings of Eric I Richman


Eric I Richman Form 4 Trading Tracker

According to the SEC Form 4 filings, Eric I Richman has made a total of 0 transactions in ADMA Biologics Inc (ADMA) over the past 5 years. The most-recent trade in ADMA Biologics Inc is the acquisition of 5,230 shares on June 8, 2018, which cost Eric I Richman around $24,999.

According to the SEC Form 4 filings, Eric I Richman has made a total of 4 transactions in Gain Therapeutics Inc (GANX) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Gain Therapeutics Inc is the acquisition of 17,000 shares on July 1, 2024, which cost Eric I Richman around $20,740.

According to the SEC Form 4 filings, Eric I Richman has made a total of 2 transactions in NeuBase Therapeutics Inc (NBSE) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in NeuBase Therapeutics Inc is the acquisition of 194 shares on March 4, 2022, which cost Eric I Richman around $6,363.

Insider Trading History of Eric I Richman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Eric I Richman Trading Performance

GuruFocus tracks the stock performance after each of Eric I Richman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Eric I Richman is 21.92%. GuruFocus also compares Eric I Richman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Eric I Richman within 3 months outperforms 7 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Eric I Richman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Eric I Richman

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
3 out of 8 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 12.15 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 11.47 LIMIT LIMIT LIMIT LIMIT LIMIT

Eric I Richman Ownership Network

Ownership Network List of Eric I Richman

No Data

Ownership Network Relation of Eric I Richman

Insider Network Chart

Eric I Richman Owned Company Details

What does NeuBase Therapeutics Inc do?

Who are the key executives at NeuBase Therapeutics Inc?

Eric I Richman is the director of NeuBase Therapeutics Inc. Other key executives at NeuBase Therapeutics Inc include 10 percent owner Symetryx Corp , 10 percent owner Barry Shiff , and 10 percent owner Aleta Shiff .

NeuBase Therapeutics Inc (NBSE) Insider Trades Summary

Over the past 18 months, Eric I Richman made no insider transaction in NeuBase Therapeutics Inc (NBSE). Other recent insider transactions involving NeuBase Therapeutics Inc (NBSE) include a net sale of 428,444 shares made by Symetryx Corp ,

In summary, during the past 3 months, insiders sold 0 shares of NeuBase Therapeutics Inc (NBSE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 489,520 shares of NeuBase Therapeutics Inc (NBSE) were sold and 61,076 shares were bought by its insiders, resulting in a net sale of 428,444 shares.

NeuBase Therapeutics Inc (NBSE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

NeuBase Therapeutics Inc Insider Transactions

No Available Data

Eric I Richman Mailing Address

Above is the net worth, insider trading, and ownership report for Eric I Richman. You might contact Eric I Richman via mailing address: C/o Rev Capital Ii, Llc, 9740 Sorrel Ave, Potomac Md 20854.